has provided consultation to Acadia Pharmaceuticals, Acumen Pharmaceuticals, ALZpath, Annovis, Aprinoia Therapeutics, Artery Therapeutics, Biogen, Biohaven, BioXcel, Bristol Myers Squibb, Eisai, Fosun, GAP Foundation, Green Valley, Janssen, Karuna, Kinoxis Therapeutics, Lighthouse Pharmaceuticals, Lilly, Lundbeck, LSP/EQT Life Sciences, Mangrove Therapeutics, Merck, MoCA Cognition, New Amsterdam, Novo Nordisk, OptoCeutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, reMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, Sinaptica, T-Neuro, TrueBinding and Vaxxinity pharmaceutical, assessment and investment companies
10.1074/jbc.M114.635144 24 Cubillos-RuizJ
Steqeyma is the latest addition to a growing list of Stelara biosimilars
Glucagonlike peptide1 receptor agonists (GLP1 RAs), also known as incretin mimetics, are a class of drugs that effectively improve glycemic control through different intrinsic effects like increasing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying [1]
